FeesSafety
Pluang+

Algoma Steel reports Q3 loss of $129.6M amid transition to electric arc furnace steelmaking.

Company Fundamentals
29 Oct 2026, 00:30 WIB
GlobeNewsWire
View Source
Neutral
Algoma Steel reports Q3 loss of $129.6M amid transition to electric arc furnace steelmaking.

Algoma Steel Group Inc. reported a net loss of $129.6 million for Q3 2026, reflecting its transition from blast furnace to electric arc furnace (EAF) steelmaking. Revenue dropped to $249.4 million from $523.9 million a year earlier due to lower shipments and tariff impacts, but adjusted EBITDA loss improved to $13.9 million. The company achieved first steel production at its second EAF unit and restored full power at its Lake Superior Power facility, positioning it for increased production and reduced carbon emissions. Algoma is focusing on a plate-first strategy amid ongoing U.S. tariffs, aiming to strengthen its Canadian market presence and improve profitability.

Algoma Steel Group Inc.'s Q3 2026 financial results provide context for readers. For those following the Basic Materials sector, 45 of 83 US stocks rose while 37 fell on Pluang as of Oct 29, 2026 03:52 WIB. Notable movers include Corteva Inc. (CTVA) at USD 11.31 with 89% buy orders, B2Gold Corp (BTG) at USD 5.11 with 60% sell orders, and Hycroft Mining Holding (HYMC) at USD 17.30 with a typical hold time of 14 days.

More News

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
22 minutes ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
22 minutes ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
22 minutes ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
2 hours ago
Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...

Market News
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App